CHF357.80
0.83%
SIX Swiss Exchange, Oct 02, 05:30 pm CEST. Closed.
ISIN
CH0019396990
Symbol
YPSN

Ypsomed Target price 2026 - Analyst rating & recommendation

Ypsomed Classifications & Recommendation

Buy
78%
Hold
17%
Sell
6%

Ypsomed Price Target

Target Price CHF408.00
Price CHF357.80
Potential
Number of Estimates 13
13 Analysts have issued a price target Ypsomed 2027 . The average Ypsomed target price is CHF408.00. This is higher than the current stock price. The highest price target is
CHF504.00 40.86%
register free of charge
, the lowest is
CHF282.80 20.96%
register free of charge
.
A rating was issued by 18 analysts: 14 Analysts recommend Ypsomed to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ypsomed stock has an average upside potential 2027 of . Most analysts recommend the Ypsomed stock at Purchase.

Sales and Margin forecast 2027, 2028 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Revenue Million CHF 730.98 715.23
2.39% 2.15%
EBITDA Margin 37.20% 43.42%
31.05% 16.71%
Net Margin 30.36% 24.96%
159.84% 17.79%

14 Analysts have issued a sales forecast Ypsomed 2027 . The average Ypsomed sales estimate is

CHF715m
unlock
. This is
2.15% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF743m 1.65%
unlock
, the lowest is
CHF684m 6.42%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 CHF731m 2.39%
2027
CHF715m 2.15%
unlock
2028
CHF803m 12.26%
unlock
2029
CHF912m 13.54%
unlock
2030
CHF1.0b 14.52%
unlock
2031
CHF1.1b 9.20%
unlock
2032
CHF1.5b 28.51%
unlock

14 Analysts have issued an Ypsomed EBITDA forecast 2027. The average Ypsomed EBITDA estimate is

CHF311m
unlock
. This is
14.20% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF340m 25.10%
unlock
, the lowest is
CHF284m 4.50%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 CHF272m 27.92%
2027
CHF311m 14.20%
unlock
2028
CHF343m 10.33%
unlock
2029
CHF393m 14.76%
unlock
2030
CHF445m 13.24%
unlock
2031
CHF456m 2.52%
unlock
2032
CHF694m 52.10%
unlock

EBITDA Margin

2026 37.20% 31.05%
2027
43.42% 16.71%
unlock
2028
42.67% 1.73%
unlock
2029
43.13% 1.08%
unlock
2030
42.65% 1.11%
unlock
2031
40.04% 6.12%
unlock

14 Ypsomed Analysts have issued a net profit forecast 2027. The average Ypsomed net profit estimate is

CHF179m
unlock
. This is
19.55% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF195m 12.15%
unlock
, the lowest is
CHF160m 28.00%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 CHF222m 153.63%
2027
CHF179m 19.55%
unlock
2028
CHF199m 11.65%
unlock
2029
CHF233m 16.95%
unlock
2030
CHF260m 11.73%
unlock
2031
CHF274m 5.37%
unlock

Net Margin

2026 30.36% 159.84%
2027
24.96% 17.79%
unlock
2028
24.83% 0.52%
unlock
2029
25.57% 2.98%
unlock
2030
24.95% 2.42%
unlock
2031
24.08% 3.49%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Earnings Per Share CHF 16.31 13.58
154.45% 16.74%
P/E 26.35
EV/Sales 7.01

14 Analysts have issued a Ypsomed forecast for earnings per share. The average Ypsomed EPS is

CHF13.58
unlock
. This is
16.94% lower
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
CHF14.83 9.30%
unlock
, the lowest is
CHF12.15 25.69%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 CHF16.31 154.45%
2027
CHF13.58 16.74%
unlock
2028
CHF15.16 11.63%
unlock
2029
CHF17.73 16.95%
unlock
2030
CHF19.81 11.73%
unlock
2031
CHF20.87 5.35%
unlock

P/E ratio

Current 21.88 57.94%
2027
26.35 20.41%
unlock
2028
23.60 10.44%
unlock
2029
20.18 14.49%
unlock
2030
18.06 10.51%
unlock
2031
17.14 5.09%
unlock

Based on analysts' sales estimates for 2027, the Ypsomed stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.85
2027
7.01 2.28%
unlock
2028
6.24 10.92%
unlock
2029
5.50 11.93%
unlock
2030
4.80 12.68%
unlock
2031
4.40 8.42%
unlock
2032
3.42 22.18%
unlock

P/S ratio

Current
2027
6.68 2.20%
unlock
2028
5.95 10.92%
unlock
2029
5.24 11.93%
unlock
2030
4.58 12.68%
unlock
2031
4.19 8.42%
unlock
2032
3.26 22.18%
unlock

Current Ypsomed Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BNP PARIBAS
Locked
➜
Locked
Locked Sep 23 2026
KEYBANC CAPITAL MARKETS INC.
Locked
➜
Locked
Locked Sep 21 2026
JEFFERIES
Locked
➜
Locked
Locked Sep 09 2026
JEFFERIES
Locked
➜
Locked
Locked Jul 09 2026
JEFFERIES
Locked
➜
Locked
Locked Jul 08 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jun 08 2026
STIFEL EUROPE
Locked
➜
Locked
Locked Jun 07 2026
Analyst Rating Date
Locked
BNP PARIBAS:
Locked
➜
Locked
Sep 23 2026
Locked
KEYBANC CAPITAL MARKETS INC.:
Locked
➜
Locked
Sep 21 2026
Locked
JEFFERIES:
Locked
➜
Locked
Sep 09 2026
Locked
JEFFERIES:
Locked
➜
Locked
Jul 09 2026
Locked
JEFFERIES:
Locked
➜
Locked
Jul 08 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jun 08 2026
Locked
STIFEL EUROPE:
Locked
➜
Locked
Jun 07 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today